Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.47 USD | -0.51% | -2.90% | +18.91% |
Financials (USD)
Sales 2024 * | 37.13M | Sales 2025 * | 25.7M | Capitalization | 699M |
---|---|---|---|---|---|
Net income 2024 * | -165M | Net income 2025 * | -203M | EV / Sales 2024 * | 10.7 x |
Net cash position 2024 * | 304M | Net cash position 2025 * | 314M | EV / Sales 2025 * | 15 x |
P/E ratio 2024 * |
-4.28
x | P/E ratio 2025 * |
-4.16
x | Employees | 117 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.1% |
Latest transcript on AnaptysBio, Inc.
1 day | -0.51% | ||
1 week | -1.09% | ||
Current month | +4.64% | ||
1 month | +19.75% | ||
3 months | +11.91% | ||
6 months | +77.00% | ||
Current year | +18.91% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel Faga
CEO | Chief Executive Officer | 44 | 21-11-25 |
Dennis Mulroy
DFI | Director of Finance/CFO | 69 | 20-07-14 |
Paul Lizzul
CTO | Chief Tech/Sci/R&D Officer | 49 | 20-07-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Hollings Renton
BRD | Director/Board Member | 77 | 15-06-29 |
Dennis Fenton
BRD | Director/Board Member | 72 | 18-03-04 |
Magda Marquet
BRD | Director/Board Member | 65 | 21-01-17 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.08% | 0 M€ | 0.00% | - | |
0.07% | 0 M€ | 0.00% | - | |
0.02% | 430 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-16 | 25.47 | -0.51% | 184,130 |
24-05-15 | 25.6 | +1.35% | 216,018 |
24-05-14 | 25.26 | +5.29% | 272,554 |
24-05-13 | 23.99 | +2.48% | 433,285 |
24-05-10 | 23.41 | -10.75% | 325,459 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+18.91% | 699M | |
+8.29% | 113B | |
+10.21% | 106B | |
+0.41% | 22.27B | |
-11.90% | 22.22B | |
-5.99% | 19.43B | |
-37.36% | 17.87B | |
-5.17% | 17.24B | |
+7.70% | 14.29B | |
+37.65% | 12.52B |
- Stock Market
- Equities
- ANAB Stock